PRESS RELEASE
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Updated overall survival (OS) data from Phase 1b metastatic cutaneous melanoma trial
Oral presentation as part of Clinical Science Symposium and two poster presentations
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 26 May 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases today announces it will deliver an oral presentation and two poster presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from June 3 – 7, 2022.
CLINICAL SCIENCE SYMPOSIUM
Title: Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
- Presenter: Mark Middleton
- Date and Time: June 5, 2022; 9:45 a.m. CDT
- Session: Clinical Science Symposium: Bispecifics: Are two better than one?
- Abstract ID: 104
POSTER PRESENTATIONS & ABSTRACTS
Title: Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM)
- Presenter: Ryan Sullivan
- Date and Time: June 6,…
